Targeted therapy for metastatic renal cell carcinoma

Metastatic renal cell carcinoma (RCC) has historically been refractory to cytotoxic and hormonal agents; only interleukin 2 and interferon alpha provide response in a minority of patients. We reviewed RCC biology and explored the ways in which this understanding led to development of novel, effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, P H, Chaganti, R S K, Motzer, R J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361211/
https://www.ncbi.nlm.nih.gov/pubmed/16465192
http://dx.doi.org/10.1038/sj.bjc.6602978
_version_ 1782153160504115200
author Patel, P H
Chaganti, R S K
Motzer, R J
author_facet Patel, P H
Chaganti, R S K
Motzer, R J
author_sort Patel, P H
collection PubMed
description Metastatic renal cell carcinoma (RCC) has historically been refractory to cytotoxic and hormonal agents; only interleukin 2 and interferon alpha provide response in a minority of patients. We reviewed RCC biology and explored the ways in which this understanding led to development of novel, effective targeted therapies. Small molecule tyrosine kinase inhibitors, monoclonal antibodies and novel agents are all being studied, and phase II studies show promising activity of sunitinib, sorafenib and bevacizumab. The results of phase III studies will determine the role of these agents in metastatic RCC.
format Text
id pubmed-2361211
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23612112009-09-10 Targeted therapy for metastatic renal cell carcinoma Patel, P H Chaganti, R S K Motzer, R J Br J Cancer Minireview Metastatic renal cell carcinoma (RCC) has historically been refractory to cytotoxic and hormonal agents; only interleukin 2 and interferon alpha provide response in a minority of patients. We reviewed RCC biology and explored the ways in which this understanding led to development of novel, effective targeted therapies. Small molecule tyrosine kinase inhibitors, monoclonal antibodies and novel agents are all being studied, and phase II studies show promising activity of sunitinib, sorafenib and bevacizumab. The results of phase III studies will determine the role of these agents in metastatic RCC. Nature Publishing Group 2006-03-13 2006-02-07 /pmc/articles/PMC2361211/ /pubmed/16465192 http://dx.doi.org/10.1038/sj.bjc.6602978 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Minireview
Patel, P H
Chaganti, R S K
Motzer, R J
Targeted therapy for metastatic renal cell carcinoma
title Targeted therapy for metastatic renal cell carcinoma
title_full Targeted therapy for metastatic renal cell carcinoma
title_fullStr Targeted therapy for metastatic renal cell carcinoma
title_full_unstemmed Targeted therapy for metastatic renal cell carcinoma
title_short Targeted therapy for metastatic renal cell carcinoma
title_sort targeted therapy for metastatic renal cell carcinoma
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361211/
https://www.ncbi.nlm.nih.gov/pubmed/16465192
http://dx.doi.org/10.1038/sj.bjc.6602978
work_keys_str_mv AT patelph targetedtherapyformetastaticrenalcellcarcinoma
AT chagantirsk targetedtherapyformetastaticrenalcellcarcinoma
AT motzerrj targetedtherapyformetastaticrenalcellcarcinoma

Ejemplares similares